Latest broker research reports from ICICI Securities Limited buy, sell, hold, neutral recommendations along with
share price targets forecast and upside.
- This broker has downgraded this stock from it's previous report. (eg. - Buy->Hold)
- Broker has maintained previous recommendation but reduced share price target.
- This broker has upgraded this stock from it's previous report.(eg. - Sell->Hold)
- Broker has maintained previous recommendation but increased share price target.
Prudent Corporate Advisory Services (Prudent) has progressed well in terms of AUM growth aided by MTM, traction in SIP and growth in MFDs. AUM/gross SIP flows/MFD count clocked CAGR of 40%/20%/19% between FY20–25 and grew 13.9% QoQ / 27.7% YoY /12.8% YoY in Q1FY26, respectively.
Lupin’s Q1FY26 result was largely in-line with our estimates. Launch of Tolvaptan in US (180 days exclusivity) helped Lupin offset the impact of price erosion in its US portfolio and a muted performance in India.
Bharti Hexacom’s (BHL) Q1FY26 print was weaker than expected due to lower roaming revenue on seasonality, and external events impacting number of inroamers; and higher other expenses on certain USOF site related cost, partly offset by employee cost provision reversal.
In Q1FY26, Blackbuck’s core business growth accelerated to ~40% YoY vs. I-Sec est. of 33% YoY. This was driven by higher uptake in value-added services in payments and growth in telematics (regulatory tailwinds).
Siemens Energy India (SEI) is operating in one of the best plays in energy transition – the ongoing grid expansion. It is amongst the leading players providing transmission equipment.
Alembic Pharma’s (Alembic) Q1FY26 result was in line with our expectations. Revenue growth was mainly driven by US (13% YoY) and ex-US international business (21% YoY). India growth was tepid at 4.7% YoY due to challenges in specialty portfolio (up 1% YoY) and slowdown in acute market.
HealthCare Global Enterprises’ (HCG) Q1FY26 result was in line with our expectations. Revenue grew 16.7% YoY driven by new centres in Mumbai (+28% YoY), Kolkata (+17% YoY) and Ahmedabad (+22% YoY) while key cluster of Karnataka and East India grew at a moderate pace.
ABB India (ABB) reported disappointing numbers in Q2CY25 on both ordering and financial fronts. While the orderbook (OB) was healthy at INR 100.6bn as of Jun’25 (book-to-bill of 0.8), order inflow (OI) fell 12% YoY.